KIT and gastrointestinal stromal tumor: CX4945 treatment led to a decrease in phosphorylated CDC37 and KIT in GIST-T1, GIST882 and GIST48, and inactivated downstream signalling intermediates AKT and S6 in a dose-dependent manner.